



ELSEVIER

Contents lists available at ScienceDirect

Data in Brief

journal homepage: www.elsevier.com/locate/dib



Data Article

Impact of cardiovascular and immunologic variables on subclinical carotid atherosclerosis in subjects with anti-phospholipid antibodies



Matteo Nicola Dario Di Minno^{a,*}, Giacomo Emmi^b,
Pasquale Ambrosino^c, Antonella Scalera^c, Antonella Tufano^c,
Giovanni Cafaro^c, Rosario Peluso^c, Alessandra Bettiol^d,
Gerardo Di Scala^b, Elena Silvestri^b, Domenico Prisco^b

^a Department of Translational Medical Sciences, Federico II University, Naples, Italy

^b Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

^c Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy

^d Department of Neurosciences, Psychology, Pharmacology and Child Health (NEUROFARBA), University of Florence, Florence, Italy

ARTICLE INFO

Article history:

Received 5 June 2018

Received in revised form

8 June 2018

Accepted 21 June 2018

Available online 27 June 2018

ABSTRACT

Whereas some previous data on carriers with isolated antiphospholipid antibodies positivity (APP) suggested an increased risk of arterial events in this clinical setting, no data are available on subclinical atherosclerosis in this clinical setting. This article reports data on intima-media thickness of the common carotid artery (CCA-IMT) and of the Bulb (Bulb-IMT) and on the prevalence of carotid plaques in APP carriers and in subjects with antiphospholipid syndrome (APS) specifically stratifying for the presence of thrombotic manifestations, cardiovascular risk factors, antibody isotype and concomitant Systemic Lupus Erythematosus (SLE) or other autoimmune diseases.

© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license

(<http://creativecommons.org/licenses/by/4.0/>).

DOI of original article: <https://doi.org/10.1016/j.ijcard.2018.06.010>

* Corresponding author.

E-mail address: dario.diminno@hotmail.it (M.N.D. Di Minno).

<https://doi.org/10.1016/j.dib.2018.06.083>

2352-3409/© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Specifications Table

Subject area	Medicine
More specific subject area	Vascular medicine
Type of data	Common carotid artery intima-media thickness (CCA-IMT), intima-media thickness at the level of carotid Bulb (Bulb-IMT) and prevalence of carotid plaques in subjects with antiphospholipid syndrome (APS), in carriers with isolated antiphospholipid antibodies positivity (APP) and controls stratified for the presence of thrombotic manifestations and cardiovascular risk factors, antibody isotype and Systemic Lupus Erythematosus (SLE) or other autoimmune diseases
How data was acquired	Ultrasound machine (MyLab 25 Gold, Esaote, Florence, Italy) with a 7.5–12 MHz linear-array transducer.
Data format	Mean with standard deviations analyzed with t-test for continuous data and percentages analyzed with the χ^2 test for categorical variables
Data source location	Federico II University, Naples, Italy

Value of the data

- We here report data on common carotid artery intima-media thickness (CCA-IMT), intima-media thickness at the level of carotid Bulb (Bulb-IMT) and prevalence of carotid plaques in subjects with antiphospholipid syndrome (APS) and in carriers with isolated antiphospholipid antibodies positivity (APP) stratifying for the type of thrombotic manifestations, for the presence of cardiovascular risk factors, antibody isotype and concomitant Systemic Lupus Erythematosus (SLE) or other autoimmune diseases.
- Cardiovascular and immunologic variables impact on subclinical atherosclerosis and data corrected for these potential confounders are needed.
- These data can be useful to be combined with data from other studies in the frame of a meta-analysis.

1. Data

Data on CCA-IMT, Bulb-IMT and on the prevalence of carotid plaques in APS subjects, in APP carriers and in matched controls stratified for the presence of thrombotic manifestations and cardiovascular risk factors, antibody isotype and Systemic Lupus Erythematosus (SLE) or other autoimmune diseases [1].

2. Experimental design, materials, and methods

As further detailed elsewhere (<http://doi.org/10.1016/j.ijcard.2018.06.010>) consecutive subjects with a persistent positivity for antiphospholipid antibodies (lupus anticoagulant [LA], IgG and IgM anti-cardiolipin [aCL], IgG and IgM anti- β_2 glycoprotein-I [$\alpha\beta_2$ GPI]) [2] were classified as APS in the presence of a history of an objectively documented venous and/or arterial thrombosis and/or with recurrent miscarriage or as APP when clinical history, physical examination and diagnostic procedures (electrocardiogram and vascular ultrasound) excluded the presence of symptomatic and/or asymptomatic venous and/or arterial thrombotic events and of recurrent miscarriages. Data about cardiovascular risk factors were recorded according to the National Cholesterol Education Program (NCEP) criteria [3]. An ultrasound assessment of carotid intima-media thickness (IMT) was performed as previously described [4] to evaluate CCA-IMT, Bulb-IMT and the presence of carotid plaques, defined as an $IMT \geq 1.3$ mm.

Table 1

Common Carotid Artery Intima-Media Thickness (CCA-IMT), intima-media thickness at the level of carotid Bulb (Bulb-IMT) and prevalence of carotid plaques in carriers of antiphospholipid antibodies positivity (APP), subjects with antiphospholipid syndrome (APS) and controls, stratified for the type of thrombotic manifestation.

	CCA-IMT (mm)	P vs Controls	P vs APP
Controls	0.82 ± 0.12	Comparator	0,032
Arterial APS	1.09 ± 0.68	< 0,001	< 0,001
Non-arterial APS	0.88 ± 0.29	0,035	1,000
APP	0.89 ± 0.25	0,032	Comparator
	Bulb-IMT (mm)	P vs Controls	P vs APP
Controls	0.95 ± 0.18	Comparator	0,009
Arterial APS	1.43 ± 0.89	< 0,001	< 0,001
Non-arterial APS	1.18 ± 0.56	< 0,001	0,807
APP	1.10 ± 0.45	0,009	Comparator
	Carotid Plaques n (%)	P vs Controls	P vs APP
Controls	33 (10.2%)	Comparator	< 0,001
Arterial APS	24 (49.0%)	< 0,001	0,077
Non-arterial APS	61 (35.5%)	< 0,001	0,795
APP	35 (33.7%)	< 0,001	Comparator

Note: Arterial APS includes cardiovascular and cerebrovascular events; Non-arterial APS includes venous thrombosis and recurrent miscarriage.

Table 2

Common Carotid Artery Intima-Media Thickness (CCA-IMT), intima-media thickness at the level of carotid Bulb (Bulb-IMT) and prevalence of carotid plaques in carriers of antiphospholipid antibodies positivity (APP), subjects with antiphospholipid syndrome (APS) and controls. Sub-analysis in subjects without cardiovascular risk factors.

Variable	Controls (n = 63)	APP (n = 29)	P vs controls	APS (n = 43)	P vs controls	P vs APP
CCA-IMT (mm)	0.71 ± 0.22	0.81 ± 0.19	0.037	0.85 ± 0.28	0.005	0.504
Bulb-IMT (mm)	0.83 ± 0.22	1.04 ± 0.46	0.007	1.09 ± 0.58	0.001	0.699
Plaques n (%)	4 (6.35%)	6 (20.7%)	0.051	10 (23.2%)	0.017	0.797

Plaques: defined as IMT ≥ 1.3 mm.

Statistical analysis was performed with the IBM SPSS 22 system (SPSS Inc., Chicago, IL, USA). Continuous data were expressed as mean ± standard deviation (SD). The *t*-test was performed to compare continuous variables and categorical variables were expressed as % and analyzed with the χ^2 test. When the minimum expected value was < 5, the Fisher's exact test was used. All the results are presented as 2-tailed values with statistical significance if *p* values < 0.05.

2.1. Effect of different types of thrombotic events on subclinical atherosclerosis

APS subjects with arterial thrombotic manifestations showed the highest CCA-IMT and Bulb-IMT values, and the highest prevalence of carotid plaques. The difference was significant both versus controls and versus APP carriers. In contrast, APS subjects with non-arterial thrombotic events (including venous thrombosis and recurrent miscarriage) showed a more severe atherosclerosis than controls, whereas no difference was found as compared to APP carriers (Table 1).

2.2. Effect of cardiovascular risk factors on subclinical atherosclerosis

To also evaluate whether traditional cardiovascular risk factors might impact on the difference in subclinical atherosclerosis found among APS subjects, APP carriers and controls, we repeated analyses




Fig. 1. Common Carotid Artery Intima-Media Thickness (CCA-IMT), Intima-Media thickness at the level of carotid bulb (Bulb-IMT) in carriers of antiphospholipid antibodies positivity (APP), subjects with antiphospholipid syndrome (APS) and controls stratified according to the antiphospholipid antibody isotype.




Fig. 2. Common Carotid Artery Intima-Media Thickness (CCA-IMT) and Intima-Media thickness at the level of carotid bulb (Bulb-IMT) in carriers of antiphospholipid antibodies positivity (APP), subjects with antiphospholipid syndrome (APS) and controls after excluding subjects with positivity for Systemic Lupus Erythematosus or other autoimmune diseases.

only selecting subjects without any cardiovascular risk factor, and we found a significantly higher CCA-IMT and Bulb-IMT with a marginally significantly higher prevalence of carotid plaques both in APP carriers and in APS subjects, as compared with controls (Table 2).

2.3. Effect of antiphospholipid antibody isotype on subclinical atherosclerosis

Some evidence [5] suggested that IgG and IgM isotypes of antiphospholipid antibodies define different subsets of thrombo-embolic events with IgG being most prevalent in subjects with venous thrombosis, IgM being primarily found among patients with arterial events. Thus, we have evaluated CCA-IMT, Bulb-IMT and the prevalence of carotid plaques stratifying population according to the antiphospholipid antibody isotype (Fig. 1).

2.4. Effect of co-existing auto-immunity disorders on subclinical atherosclerosis

To avoid the potential confounding effect of co-existing autoimmune diseases on subclinical atherosclerosis [6], all the analyses were repeated after excluding subjects with Systemic Lupus Erythematosus (SLE) or other autoimmune diseases and, as compared with controls, a higher CCA-IMT, Bulb-IMT and prevalence of carotid plaques were confirmed in APP carriers and in APS subjects (Fig. 2).

Acknowledgments

Nothing to report.

Transparency document. Supplementary material

Transparency document associated with this article can be found in the online version at <https://doi.org/10.1016/j.dib.2018.06.083>.

References

- [1] <http://dx.doi.org/10.1016/j.ijcard.2018.06.010>.
- [2] K.M. Devreese, S.S. Pierangeli, B. de Laat, A. Tripodi, T. Atsumi, T.L. Ortel, Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH, *J. Thromb. Haemost.* 12 (2014) 792–795.
- [3] M.N. Di Minno, A. Tufano, A. Guida, et al., Abnormally high prevalence of major components of the metabolic syndrome in subjects with early-onset idiopathic venous thromboembolism, *Thromb. Res.* 127 (2011) 193–197.
- [4] M.N. Di Minno, S. Iervolino, R. Peluso, R. Scarpa, G. Di Minno, CaRRDs study group, Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor- α blockers and traditional disease-modifying antirheumatic drugs, *Arterioscler. Thromb. Vasc. Biol.* 31 (2011) 705–712.
- [5] H. Locht, A. Wiik, IgG and IgM isotypes of anti-cardiolipin and anti-beta2-glycoprotein I antibodies reflect different forms of recent thrombo-embolic events, *Clin. Rheumatol.* 25 (2006) 246–250.
- [6] M.N. Di Minno, S. Iervolino, R. Lupoli, A. Russoiillo, A. Coppola, R. Peluso, R. Scarpa, G. Di Minno, Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis, *Semin Thromb. Hemost.* 38 (2012) 497–505.